Beigene Ltd (BGNE)

$152.17

+1.67

(+1.11%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Beigene Ltd

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 634.40M → 751.65M (in $), with an average increase of 15.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -367.55M → -251.15M (in $), with an average increase of 46.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 80.7% return, outperforming this stock by 102.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 222.8% return, outperforming this stock by 277.3%

Performance

  • $151.92
    $158.94
    $152.17
    downward going graph

    0.16%

    Downside

    Day's Volatility :4.42%

    Upside

    4.26%

    downward going graph
  • $126.97
    $225.23
    $152.17
    downward going graph

    16.56%

    Downside

    52 Weeks Volatility :43.63%

    Upside

    32.44%

    downward going graph

Returns

PeriodBeigene LtdSector (Health Care)Index (Russel 2000)
3 Months
6.51%
6.1%
0.0%
6 Months
-14.1%
4.9%
0.0%
1 Year
-21.64%
13.6%
0.0%
3 Years
-54.55%
14.3%
-22.5%

Highlights

Market Capitalization
16.2B
Book Value
$32.13
Earnings Per Share (EPS)
-7.54
PEG Ratio
0.0
Wall Street Target Price
266.85
Profit Margin
-28.39%
Operating Margin TTM
-34.77%
Return On Assets TTM
-11.81%
Return On Equity TTM
-20.87%
Revenue TTM
2.8B
Revenue Per Share TTM
26.46
Quarterly Revenue Growth YOY
67.9%
Gross Profit TTM
-511.1M
EBITDA
-1.0B
Diluted Eps TTM
-7.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-9.03
EPS Estimate Next Year
-4.38
EPS Estimate Current Quarter
-2.77
EPS Estimate Next Quarter
-2.36

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Beigene Ltd(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 75.36%

Current $152.17
Target $266.85

Company Financials

FY18Y/Y Change
Revenue
198.2M
↓ 16.85%
Net Income
-673.8M
↑ 623.67%
Net Profit Margin
-339.91%
↓ 300.85%
FY19Y/Y Change
Revenue
428.2M
↑ 116.03%
Net Income
-950.6M
↑ 41.08%
Net Profit Margin
-221.99%
↑ 117.92%
FY20Y/Y Change
Revenue
308.9M
↓ 27.87%
Net Income
-1.6B
↑ 68.37%
Net Profit Margin
-518.18%
↓ 296.19%
FY21Y/Y Change
Revenue
1.2B
↑ 280.83%
Net Income
-1.4B
↓ 11.69%
Net Profit Margin
-120.15%
↑ 398.03%
FY22Y/Y Change
Revenue
1.4B
↑ 20.37%
Net Income
-2.0B
↑ 41.78%
Net Profit Margin
-141.52%
↓ 21.37%
FY23Y/Y Change
Revenue
2.5B
↑ 73.65%
Net Income
-881.7M
↓ 56.0%
Net Profit Margin
-35.86%
↑ 105.66%
Q4 FY22Q/Q Change
Revenue
380.1M
↓ 1.94%
Net Income
-445.3M
↓ 20.13%
Net Profit Margin
-117.16%
↑ 26.68%
Q1 FY23Q/Q Change
Revenue
447.8M
↑ 17.81%
Net Income
-348.4M
↓ 21.76%
Net Profit Margin
-77.81%
↑ 39.35%
Q2 FY23Q/Q Change
Revenue
595.3M
↑ 32.93%
Net Income
-381.1M
↑ 9.39%
Net Profit Margin
-64.03%
↑ 13.78%
Q3 FY23Q/Q Change
Revenue
781.3M
↑ 31.25%
Net Income
215.4M
↓ 156.52%
Net Profit Margin
27.57%
↑ 91.6%
Q4 FY23Q/Q Change
Revenue
634.4M
↓ 18.8%
Net Income
-367.6M
↓ 270.63%
Net Profit Margin
-57.94%
↓ 85.51%
Q1 FY24Q/Q Change
Revenue
751.7M
↑ 18.48%
Net Income
-251.2M
↓ 31.67%
Net Profit Margin
-33.41%
↑ 24.53%
FY18Y/Y Change
Total Assets
2.2B
↑ 114.98%
Total Liabilities
496.0M
↑ 36.93%
FY19Y/Y Change
Total Assets
1.6B
↓ 28.33%
Total Liabilities
633.9M
↑ 27.8%
FY20Y/Y Change
Total Assets
5.6B
↑ 247.38%
Total Liabilities
1.7B
↑ 173.14%
FY21Y/Y Change
Total Assets
8.6B
↑ 54.37%
Total Liabilities
2.4B
↑ 38.78%
FY22Y/Y Change
Total Assets
6.4B
↓ 26.22%
Total Liabilities
2.0B
↓ 16.94%
FY23Y/Y Change
Total Assets
5.8B
↓ 9.0%
Total Liabilities
2.2B
↑ 11.91%
Q4 FY22Q/Q Change
Total Assets
6.4B
↓ 5.15%
Total Liabilities
2.0B
↓ 3.62%
Q1 FY23Q/Q Change
Total Assets
6.0B
↓ 6.62%
Total Liabilities
1.8B
↓ 9.84%
Q2 FY23Q/Q Change
Total Assets
5.7B
↓ 3.83%
Total Liabilities
1.9B
↑ 7.26%
Q3 FY23Q/Q Change
Total Assets
5.5B
↓ 3.56%
Total Liabilities
1.8B
↓ 8.73%
Q4 FY23Q/Q Change
Total Assets
5.8B
↑ 5.08%
Total Liabilities
2.2B
↑ 26.8%
Q1 FY24Q/Q Change
Total Assets
5.7B
↓ 2.37%
Total Liabilities
2.3B
↑ 1.82%
FY18Y/Y Change
Operating Cash Flow
-547.7M
↓ 4395.15%
Investing Cash Flow
-637.6M
↑ 78.94%
Financing Cash Flow
1.7B
↑ 244.76%
FY19Y/Y Change
Operating Cash Flow
-750.3M
↑ 36.98%
Investing Cash Flow
554.2M
↓ 186.91%
Financing Cash Flow
85.7M
↓ 94.93%
FY20Y/Y Change
Operating Cash Flow
-1.3B
↑ 71.07%
Investing Cash Flow
-3.2B
↓ 671.74%
Financing Cash Flow
5.2B
↑ 5972.39%
FY21Y/Y Change
Operating Cash Flow
-1.3B
↑ 1.19%
Investing Cash Flow
640.7M
↓ 120.22%
Financing Cash Flow
3.6B
↓ 30.1%
FY22Y/Y Change
Operating Cash Flow
-1.5B
↑ 15.24%
Investing Cash Flow
1.1B
↑ 68.13%
Financing Cash Flow
-19.0M
↓ 100.52%
Q4 FY22Q/Q Change
Operating Cash Flow
-318.2M
↓ 43.37%
Investing Cash Flow
38.5M
↓ 77.26%
Financing Cash Flow
-110.4M
↓ 191.79%
Q1 FY23Q/Q Change
Operating Cash Flow
-563.8M
↑ 77.18%
Investing Cash Flow
67.8M
↑ 75.94%
Financing Cash Flow
-19.9M
↓ 82.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-293.9M
↓ 47.87%
Investing Cash Flow
67.8M
↑ 0.0%
Financing Cash Flow
166.1M
↓ 935.92%
Q3 FY23Q/Q Change
Operating Cash Flow
-78.2M
↓ 73.41%
Investing Cash Flow
-186.3M
↓ 374.74%
Financing Cash Flow
-76.8M
↓ 146.23%

Technicals Summary

Sell

Neutral

Buy

Beigene Ltd is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Beigene Ltd
Beigene Ltd
-10.48%
-14.1%
-21.64%
-54.55%
22.66%
Moderna, Inc.
Moderna, Inc.
-16.86%
15.92%
-2.46%
-48.68%
764.93%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.12%
15.76%
50.37%
88.19%
269.25%
Novo Nordisk A/s
Novo Nordisk A/s
-2.42%
30.45%
80.67%
222.84%
488.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.43%
13.55%
42.21%
148.12%
179.95%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Beigene Ltd
Beigene Ltd
NA
NA
0.0
-9.03
-0.21
-0.12
NA
32.13
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Beigene Ltd
Beigene Ltd
Buy
$16.2B
22.66%
NA
-28.39%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
764.93%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
269.25%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
488.09%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
179.95%
31.94
39.46%

Institutional Holdings

  • Baker Bros Advisors LP

    10.11%
  • Capital Research & Mgmt Co - Division 3

    6.76%
  • Hillhouse Capital Advisors, Ltd.

    4.95%
  • PRIMECAP Management Company

    4.78%
  • Baillie Gifford & Co Limited.

    3.57%
  • Temasek Holdings Ltd.

    2.88%

Corporate Announcements

  • Beigene Ltd Earnings

    Beigene Ltd’s price-to-earnings ratio stands at None

    Read More

Company Information

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Organization
Beigene Ltd
Employees
10000
CEO
Mr. John V. Oyler
Industry
Health Technology

FAQs